Atherosclerotic Cardiovascular Disease Market Positioned for Sustained Growth Through 2034, DelveInsight Finds

The Atherosclerotic Cardiovascular Disease (ASCVD) market in the 7MM (The United States, EU4—Germany, France, Italy, and Spain, the United Kingdom, and Japan) was valued at approximately USD 23,000 million in 2024 and is projected to increase during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the ASCVD landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The ASCVD market is increasingly driven by a paradigm shift from traditional lipid-lowering monotherapies toward multimodal risk reduction strategies. PCSK9 inhibitors represent a highly lucrative segment, with established agents like evolocumab (REPATHA) and alirocumab (PRALUENT) generating substantial revenues. Additionally, emerging therapeutic classes targeting elevated Lp(a) and vascular inflammation position themselves to capture significant market share during the forecast period.

DelveInsight's report, "Atherosclerotic Cardiovascular Disease (ASCVD) – Market Insights, Epidemiology, and Market Forecast – 2034," provides a comprehensive analysis of the Atherosclerotic Cardiovascular Disease (ASCVD) landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines ASCVD market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Atherosclerotic Cardiovascular Disease market outlook, drug uptake, treatment scenario and epidemiology trends, visit Atherosclerotic Cardiovascular Disease Market Forecast 

Some of the key facts of the Atherosclerotic Cardiovascular Disease Market Report:

• Key Atherosclerotic Cardiovascular Disease Companies: Amgen, Sanofi/Regeneron Pharmaceuticals, Novartis, NewAmsterdam Pharma/Menarini, AstraZeneca, Ionis Pharmaceuticals, Resverlogix, and others
• Key Atherosclerotic Cardiovascular Disease Therapies: Evolocumab (REPATHA), Alirocumab (PRALUENT), Inclisiran (LEQVIO), Olpasiran (AMG 890), Obicetrapib (TA-8995), Pelacarsen (TQJ230), Apabetalone (RVX000222), BRILINTA (ticagrelor), Low-dose colchicine (LODOCO), Statins, Ezetimibe, and others
• The Atherosclerotic Cardiovascular Disease market is expected to surge due to the disease's increasing prevalence, rising burden of comorbidities, and launching of multiple high-efficacy emerging therapies that target residual cardiovascular risk during the forecast period. Furthermore, launching various emerging therapies including novel CETP inhibitors, siRNA-based Lp(a)-lowering agents, and anti-inflammatory therapeutics will significantly revolutionize the Atherosclerotic Cardiovascular Disease market dynamics.

Atherosclerotic Cardiovascular Disease Overview

Atherosclerotic Cardiovascular Disease (ASCVD) is a medical condition characterized by the buildup of fatty deposits (plaques) on the inner walls of arteries. These plaques consist of cholesterol, fatty substances, calcium, and other cellular waste products. Over time, the plaques can harden and narrow the arteries, which reduces blood flow to vital organs and tissues. It is a progressive and chronic condition that can affect various arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). The most common manifestations of ASCVD include Coronary Artery Disease (CAD), cerebrovascular disease (stroke), and Peripheral Arterial Disease (PAD). ASCVD remains the leading global driver of morbidity and mortality, with hypertension, diabetes, dyslipidemia, and obesity accelerating plaque progression and creating complex multi-morbid patient profiles across coronary, cerebrovascular, peripheral, and aortic disease. Risk factors include smoking, environmental exposures, genetic predisposition, elevated cholesterol, high blood pressure, and sedentary lifestyle. Early detection through risk assessment and personalized treatment approaches improve patient outcomes significantly.

Key Trends in Atherosclerotic Cardiovascular Disease Therapeutics Market:

• Multimodal Risk Reduction Approach: Shift from single-agent LDL-C lowering toward combination therapies targeting lipids, inflammation, Lp(a), and thrombosis
• Expansion of PCSK9 Inhibitor Class: Growing uptake of evolocumab, alirocumab, and inclisiran for persistent LDL-C elevation in high-risk patients
• Emerging Lp(a)-Targeting Therapies: Development of siRNA-based agents (olpasiran, pelacarsen) for patients with elevated Lp(a) and established ASCVD
• Anti-Inflammatory Strategies: Adoption of colchicine and other anti-inflammatory agents targeting vascular inflammation independently of cholesterol reduction
• Novel CETP Inhibitors: Advancement of oral, selective CETP inhibitors (obicetrapib) offering improved LDL-C reduction with enhanced bioavailability
• Precision Medicine and Biomarker-Driven Strategies: Integration of lipid biomarkers (apoB, Lp(a)), inflammatory markers (hs-CRP), and genetic variants (LDLR, APOB, PCSK9) for risk stratification
• Treatment Standardization Across Geographies: Increasing alignment of clinical guidelines supporting earlier, more aggressive lipid-lowering therapy initiation

Atherosclerotic Cardiovascular Disease Epidemiology

The report section on Atherosclerotic Cardiovascular Disease (ASCVD) epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, comorbidity patterns, and data on systemic inflammation-associated ASCVD. The report highlights disease burden, risk factors, and projections for future epidemiological trends, helping stakeholders understand the scope of ASCVD and plan targeted interventions, research, and treatment strategies.

In 2024, the total diagnosed prevalent cases of ASCVD across the 7MM were approximately 65 million, and this burden is projected to rise over the forecast period. The United States accounted for approximately 30 million ASCVD cases in 2024, representing the highest disease burden among 7MM markets. In the United States, systemic inflammation–associated ASCVD cases were estimated at approximately 17 million in 2024.

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation:

The Atherosclerotic Cardiovascular Disease market report provides epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of ASCVD
• Gender-specific Diagnosed Prevalent Cases of ASCVD
• Age-specific Diagnosed Prevalent Cases of ASCVD
• Comorbidity-specific Diagnosed Prevalent Cases of ASCVD
• Systemic inflammation in ASCVD

Download the report to understand which factors are driving Atherosclerotic Cardiovascular Disease epidemiology trends @ Atherosclerotic Cardiovascular Disease Epidemiology Forecast 

Recent Developments in the ASCVD Treatment Landscape:

• In October 2025, Amgen presented detailed results from the Phase III VESALIUS-CV clinical trial of REPATHA (evolocumab) at the 2025 American Heart Association Scientific Sessions and simultaneously published findings in the New England Journal of Medicine, confirming continued efficacy in reducing cardiovascular events.
• In August 2025, Novartis announced positive results from V-DIFFERENCE, a Phase IV study evaluating inclisiran compared to placebo, in patients with hypercholesterolemia who have not achieved guideline-recommended low-density LDL-C goals, supporting the drug's role in advanced lipid management.
• In May 2025, NewAmsterdam Pharma presented additional data from the BROADWAY and TANDEM pivotal Phase III studies as late-breaking oral presentations at the European Atherosclerosis Society Congress (EAS) 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM), demonstrating significant LDL-C reductions with obicetrapib.
• In August 2025, NewAmsterdam Pharma announced that the EMA has validated the Marketing Authorization Application for obicetrapib 10 mg monotherapy and 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination for patients with primary hypercholesterolemia, both heterozygous familial and non-familial or mixed dyslipidemia, signaling nearterm regulatory approval.

Atherosclerotic Cardiovascular Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Atherosclerotic Cardiovascular Disease market or expected to get launched during the study period. The analysis covers ASCVD market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind maximal use of the drugs. Additionally, it compares the drugs based on market share and revenue contribution.

The report also covers the Atherosclerotic Cardiovascular Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atherosclerotic Cardiovascular Disease Therapies and Key Companies

• Evolocumab (REPATHA): Amgen
• Alirocumab (PRALUENT): Sanofi/Regeneron Pharmaceuticals
• Inclisiran (LEQVIO): Novartis
• BRILINTA (Ticagrelor): AstraZeneca
• Low-dose Colchicine (LODOCO): Approved in US (2023)
• Statins and Ezetimibe: Multiple developers
• Olpasiran (AMG 890): Amgen/Arrowhead Pharmaceuticals
• Obicetrapib (TA-8995): NewAmsterdam Pharma/Menarini
• Pelacarsen (TQJ230): Ionis Pharmaceuticals/Novartis
• Apabetalone (RVX000222): Resverlogix
• MK-0616: Merck
• Lerodalcibep: Under development

To know more about Atherosclerotic Cardiovascular Disease companies working in the treatment market, visit @ Atherosclerotic Cardiovascular Disease Clinical Trials and Therapeutic Assessment 

Atherosclerotic Cardiovascular Disease Market Drivers

• Increasing prevalence of ASCVD globally, with rising disease burden across all 7MM regions
• Rapid growth of diabetes, obesity, hypertension, and chronic kidney disease (CKD), accelerating ASCVD onset and severity
• Development of novel therapies targeting LDL-C, Lp(a), inflammation, and residual cardiovascular risk
• Advancements in diagnostic capabilities including biomarker testing (lipids, apoB, hs-CRP, Lp(a)), genetic profiling, and vascular imaging
• Rising healthcare expenditure and government initiatives supporting cardiovascular disease management
• Expanding awareness and proactive screening programs enabling earlier diagnosis and intervention
• Integration of precision medicine and biomarker-driven strategies enabling personalized treatment approaches
• Emerging anti-inflammatory and novel mechanistic therapies improving patient outcomes and survival rates

Atherosclerotic Cardiovascular Disease Market Barriers

• Persistent underutilization of PCSK9 inhibitors and other high-efficacy therapies despite compelling clinical evidence
• High cost of advanced therapeutics limiting patient access and adherence, particularly in resource-limited settings
• Complex clinical trial designs and lengthy regulatory approval processes for emerging therapies
• Treatment resistance and heterogeneous patient responses due to genetic and environmental factors
• Limited awareness and accessibility of novel therapies in emerging markets and underserved populations
• Safety and tolerability concerns associated with long-term use of advanced therapies
• Reimbursement challenges and variable payment policies across geographies affecting market penetration
• Suboptimal medication adherence, with fewer than 50% of high-risk patients remaining on statin therapy after the first year
• Variability in clinical guideline adoption and treatment algorithm implementation across regions

Scope of the Atherosclerotic Cardiovascular Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Atherosclerotic Cardiovascular Disease Companies: Amgen, Sanofi/Regeneron Pharmaceuticals, Novartis, NewAmsterdam Pharma/Menarini, AstraZeneca, Ionis Pharmaceuticals, Resverlogix, and others
• Key Atherosclerotic Cardiovascular Disease Therapies: Evolocumab (REPATHA), Alirocumab (PRALUENT), Inclisiran (LEQVIO), Olpasiran (AMG 890), Obicetrapib (TA-8995), Pelacarsen (TQJ230), Apabetalone (RVX000222), BRILINTA (ticagrelor), Low-dose Colchicine (LODOCO), Statins, Ezetimibe, and others
• Atherosclerotic Cardiovascular Disease Therapeutic Assessment: Current marketed and Atherosclerotic Cardiovascular Disease emerging therapies
• Atherosclerotic Cardiovascular Disease Market Dynamics: Atherosclerotic Cardiovascular Disease market drivers and Atherosclerotic Cardiovascular Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Atherosclerotic Cardiovascular Disease Unmet Needs, KOL's views, Analyst's views, Atherosclerotic Cardiovascular Disease Market Access and Reimbursement

Discover more about therapies set to grab major Atherosclerotic Cardiovascular Disease market share @ Atherosclerotic Cardiovascular Disease Treatment Market